

Insert the sequence listing pages 1-12 at the end of the specification.

### REMARKS

The specification has been amended in response to the June 21, 2001 Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures ("Notice"). Applicants submit herewith a computer readable form (CFR) copy of the "Sequence Listing," a paper copy of the "Sequence Listing," and a statement that the content of the paper and computer readable copies are the same and include no new matter, in compliance with 37 C.F.R. §§ 1.821-1.825. The specification has been amended to insert the sequence listing.

The specification is also amended to introduce reference to SEQ ID NO:38. In the original application, SEQ ID NO:38 was not assigned to the sequence FIWIQI on page 7, line 21. The amendment assigns the sequence identifier SEQ ID NO:38 to this peptide. No new matter has been introduced by this amendment.

The amendment also corrects a typographical error in claim 9 as filed. The amino acid sequence in claim 9 was originally assigned SEQ ID NO:39 and has been amended to recite SEQ ID NO:34, to correspond with the description present in the specification. The amendment to claim 9 renders the claim grammatically correct without changing its meaning; this amendment is supported at least at page 11, line 17. No new matter has been introduced by this amendment.

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page is captioned "**Version with markings to show changes made.**"

A response to the Notice is due July 21, 2001, which falls on a Saturday. Therefore, this response is due or before Monday, July 23, 2001. Applicants believe that no fee is due with this submission. However, the Commissioner is hereby authorized to charge any additional fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Attorney Reference No. 18242-507 (VI-7).

Applicants: **Hammond et al**  
U.S.S.N.: **09/543,188**

Should any questions or issues arise concerning this application, the Examiner is encouraged to contact the undersigned at the telephone number provided below.

Respectfully submitted,

*Jr.* *Hadi A. Elrifai, Reg No. 45,409*  
Ivor R. Elrifai, Reg. No.: 39,529  
Attorney for Applicants  
c/o MINTZ, LEVIN  
One Financial Center  
Boston, Massachusetts 02111  
Tel: (617) 542-6000  
Fax: (617) 542-2241

**Version with markings to show changes made**

**In the Claims:**

9. The peptide ligand of claim 7, wherein said polypeptide comprises a retro-inverso isomer of the amino acid sequence D(GGHPQGWG) (SEQ ID NO:3[9]4).

**In the Specification:**

Paragraph beginning on page 7, line 10 has been amended as follows:

For example, in various embodiments, the peptide ligands are D retro-inverso peptides. The term “retro-inverso isomer” refers to an isomer of a linear peptide in which the direction of the sequence is reversed and the chirality of each amino acid residue is inverted. *See, e.g., Jameson et al., Nature, 368: 744-746 (1994); Brady et al., Nature, 368: 692-693 (1994).* The net result of combining D-enantiomers and reverse synthesis is that the positions of carbonyl and amino groups in each amide bond are exchanged, while the position of the side-chain groups at each alpha carbon is preserved. Unless specifically stated otherwise, it is presumed that any given L-amino acid sequence of the invention may be made into an D retro-inverso peptide by synthesizing a reverse of the sequence for the corresponding native L-amino acid sequence. To illustrate, if the peptide model is the prion binding ligand peptide 110: IQIWIF (SEQ ID NO:21), formed of L-amino acids, the retro-inverso peptide analog of this peptide (formed of D-amino acids) would have the sequence, FIWIFI (SEQ ID NO:38).